---
title: "Pfizer Inc. (PFE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PFE.US.md"
symbol: "PFE.US"
name: "Pfizer Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:36:35.868Z"
locales:
  - [en](https://longbridge.com/en/quote/PFE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PFE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PFE.US.md)
---

# Pfizer Inc. (PFE.US)

## Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.pfizer.com](https://www.pfizer.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 38 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.36% |  |
| Net Profit YoY | -4.97% |  |
| P/B Ratio | 1.60 |  |
| Dividend Ratio | 6.79% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 144366920800.77 |  |
| Revenue | 63315000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.29% | B |
| Profit Margin | 11.83% | B |
| Gross Margin | 76.42% | A |
| Revenue YoY | 1.36% | C |
| Net Profit YoY | -4.97% | C |
| Total Assets YoY | -0.20% | D |
| Net Assets YoY | -0.26% | D |
| Cash Flow Margin | 159.98% | B |
| OCF YoY | 1.36% | C |
| Turnover | 0.30 | D |
| Gearing Ratio | 56.46% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Pfizer Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.97%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "6.79%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "144366920800.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "63315000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.29%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "11.83%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "76.42%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1.36%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.97%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.20%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.26%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "159.98%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1.36%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "56.46%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.27 | 34/190 | 19.62 | 16.59 | 13.30 |
| PB | 1.60 | 78/190 | 1.69 | 1.58 | 1.53 |
| PS (TTM) | 2.28 | 63/190 | 2.43 | 2.29 | 2.20 |
| Dividend Yield | 6.79% | 3/190 | 7.01% | 6.79% | 6.42% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 31% |
| Overweight | 2 | 7% |
| Hold | 15 | 52% |
| Underweight | 2 | 7% |
| Sell | 1 | 3% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 25.66 |
| Highest Target | 36.00 |
| Lowest Target | 24.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PFE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PFE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PFE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PFE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**